Former Interim President and Chief Executive Officer · ANI PHARMACEUTICALS INC (ANIP)

Patrick Walsh

FY2020 is the first fiscal year CompBrief holds for Patrick Walsh as a named executive officer of ANI PHARMACEUTICALS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$962,213

Salary $282,760Stock awards $679,308

5th of 6 named executive officers at ANI Pharmaceuticals by FY2020 total.

6 named officers on file for ANI PHARMACEUTICALS, FY2020

Patrick Walsh’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • ANIP’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ANI PHARMACEUTICALS’s whole pay program stands against its peers

  • ANI PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ANIP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2021 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Patrick Walsh’s full pay file as a PDF — free

More than this page: up to 10 years of Patrick’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Patrick Walsh compensation by year

ANI PHARMACEUTICALS Summary Compensation Table · the one fiscal year held
In US dollars, as ANI PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$282,760
Bonus$0
Stock awards$679,308
Option awards$0
Non-equity incentive$0
Pension and deferred compensation$0
All other$145
Total$962,213

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ANI PHARMACEUTICALS INC DEF 14A filed April 29, 2021, accession 0001104659-21-057727, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ANI PHARMACEUTICALS INC filed document, accession 0001104659-21-057727. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2021.

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
RSU9,255$268,765—

Per the Outstanding Equity Awards at Fiscal Year-End table in ANI PHARMACEUTICALS INC's FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

9 Form 4 lines since the FY2020 proxy (filed April 29, 2021)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-05-13Sale—10,000$80.6338,432
2026-05-11Sale—3,973$80.7548,432
2026-03-03Sale—6,000$74.2352,405
2025-11-13Sale—8,643$86.8861,405
2025-11-13Gift—3,000$0.0058,405
2025-08-15Sale—9,000$89.0570,048
2025-05-22Grant or award—4,336$0.0079,048
2024-05-21Grant or award—4,410$0.0074,712

The 8 most recent of 9 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ANI PHARMACEUTICALS’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Nikhil LalwaniPresident and Chief Executive Officer$3,715,036
Stephen CareySenior Vice President, Finance and Chief Financial Officer$2,754,577
Robert SchrepferFormer Senior Vice President, New Business Development$2,658,963
James MarkenSenior Vice President, Operations and Product Development$1,874,535
Patrick Walsh · this pageFormer Interim President and Chief Executive Officer$962,213
Arthur PrzybylFormer President and Chief Executive Officer$857,814

Board service

ANI PHARMACEUTICALS board · FY2021–FY2025
Director compensation in US dollars, as ANI PHARMACEUTICALS reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$97,477$248,323$0$0$345,800
FY2024$101,750$272,141$0—$373,891
FY2023$101,750$320,458$0—$422,208
FY2022$111,315$304,183$0—$415,498
FY2021$111,750$297,437$0—$409,187

Each year as the company reported it in ANI PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: ANI PHARMACEUTICALS pays directors a $59,250 cash retainer and $290,000 in equity. As stated in ANI PHARMACEUTICALS's FY2025 proxy.

The full ANI PHARMACEUTICALS compensation record

free company brief

This page is one person within ANI PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ANI PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Patrick Walsh's compensation dossier · One-time report. No refunds.